Commerce Bank Lowers Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Commerce Bank trimmed its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 4.5% in the 4th quarter, HoldingsChannel reports. The fund owned 75,449 shares of the medical research company’s stock after selling 3,534 shares during the quarter. Commerce Bank’s holdings in IQVIA were worth $17,457,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. US Bancorp DE lifted its stake in IQVIA by 0.6% during the fourth quarter. US Bancorp DE now owns 18,533 shares of the medical research company’s stock worth $4,288,000 after purchasing an additional 117 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC lifted its stake in IQVIA by 36.7% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 1,908 shares of the medical research company’s stock worth $441,000 after purchasing an additional 512 shares in the last quarter. Enterprise Financial Services Corp raised its stake in shares of IQVIA by 29.9% in the fourth quarter. Enterprise Financial Services Corp now owns 1,646 shares of the medical research company’s stock valued at $381,000 after acquiring an additional 379 shares in the last quarter. Central Valley Advisors LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at $1,186,000. Finally, Dai ichi Life Insurance Company Ltd raised its stake in shares of IQVIA by 30.2% in the fourth quarter. Dai ichi Life Insurance Company Ltd now owns 24,157 shares of the medical research company’s stock valued at $5,589,000 after acquiring an additional 5,609 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IQV has been the topic of several analyst reports. Truist Financial reduced their price objective on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research note on Friday, May 3rd. Barclays increased their price objective on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Guggenheim lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. UBS Group increased their target price on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Finally, SVB Leerink began coverage on IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 target price on the stock. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $257.57.

IQVIA Stock Performance

IQV traded up $2.34 during trading on Friday, reaching $229.43. The company’s stock had a trading volume of 267,636 shares, compared to its average volume of 950,439. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The company’s fifty day moving average price is $237.60 and its 200-day moving average price is $228.31. The company has a market capitalization of $41.80 billion, a price-to-earnings ratio of 31.02, a price-to-earnings-growth ratio of 2.06 and a beta of 1.52. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.19 by $0.11. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.1 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now owns 796,752 shares of the company’s stock, valued at approximately $199,610,278.56. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Kevin C. Knightly sold 8,607 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares of the company’s stock, valued at $1,313,642.67. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.